27 filings · most recent first
PRAX 8-K Filings
Praxis Precision Medicines Receives Breakthrough Therapy Designation For
Praxis Precision Medicines Inc Converts Embrave3 Study Design Following Fda
Praxis Precision Medicines Announces Positive Clinical Trial Results And Fda
Praxis Precision Medicines Reports Third Quarter 2025 Financial Results And
Praxis Precision Medicines Updates Corporate Presentation And Receives Fda
Praxis Precision Medicines Announces Positive Topline Results For
Praxis Precision Medicines Reports Topline Radiant Study Results And Second
Praxis Precision Medicines Receives Fda Breakthrough Therapy Designation For
Praxis Precision Medicines Announces Voting Results From Annual Meeting
Praxis Precision Medicines Updates Clinical Programs And Corporate Presentation
Praxis Precision Medicines Reports Q1 2025 Financial Results And Provides
Praxis Precision Medicines Announces Financial Results For Q4 And Full Year 2024
Praxis Precision Medicines Announces Corporate Strategy And Milestones For 2025
Praxis Precision Medicines Reports Third Quarter 2024 Financial Results And
Praxis Precision Medicines Reports Q2 2024 Financial Results And Corporate
Praxis Precision Medicines Inc 2024 Annual Meeting Stockholder Actions
Praxis Precision Medicines Reports Q1 2024 Financial Results And Corporate
Praxis Precision Medicines Announces Positive Results From Phase 2A Study Of
Praxis Precision Medicines Announces Financial Results And Strategic
Praxis Precision Medicines Terminates Sales Agreement
Praxis Precision Medicines Announces Cns Drug Development Collaboration And
Praxis Precision Medicines Announces Underwritten Public Offering
Praxis Precision Medicines Terminates 2024 Sales Agreement And Enters New 2025
Praxis Precision Medicines Amends Executive Severance Agreements
Praxis Precision Medicines Announces Positive Topline Results From Embold Study
Praxis Precision Medicines Announces Underwritten Offering Of Shares And
Praxis Precision Medicines Announces Public Offering Of Shares And Prefunded